ABT Stock Recent News

Abbott (ABT) reached $132.02 at the closing of the latest trading day, reflecting a -1.18% change compared to its last close.

Abbott (ABT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Abbott debuts FreeStyle Libre 3 Plus in Canada, enhancing diabetes care with the world's smallest glucose sensor.

Abbott Laboratories (NYSE:ABT) has greatly exceeded the broader S&P 500 index this year, with its stock price increasing by 18% compared to the S&P 500's 6% rise. This strong performance is due to the company's solid quarterly results and positive future forecasts.

In 2013, AbbVie (ABBV -0.93%) became a publicly traded corporation after splitting from its former parent company, Abbott Laboratories (ABT 0.18%). Since then, both have produced strong returns and have been great picks for income-seeking investors, thanks to consistent payout hikes.

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

In the closing of the recent trading day, Abbott (ABT) stood at $134.11, denoting a -1.58% move from the preceding trading day.

Abbott (ABT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

ABT stock surges 21.7% year to date on CGM sales growth and robust diagnostics demand, even as FX and macro risks weigh on forecasts.

Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.